Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.

Evrard SM, Taranchon-Clermont E, Rouquette I, Murray S, Dintner S, Nam-Apostolopoulos YC, Bellosillo B, Varela-Rodriguez M, Nadal E, Wiedorn KH, Melchior L, Andrew E, Jones M, Ridgway J, Frykman C, Lind L, Rot M, Kern I, Speel EJM, Roemen GMJM, Trincheri N, Freiberger SN, Rechsteiner M.

J Mol Diagn. 2019 Nov;21(6):1010-1024. doi: 10.1016/j.jmoldx.2019.06.010. Epub 2019 Aug 22.

2.

Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome.

Grosse C, Soltermann A, Rechsteiner M, Grosse A.

PLoS One. 2019 Aug 6;14(8):e0220691. doi: 10.1371/journal.pone.0220691. eCollection 2019.

3.

New Insights into Tumor Heterogeneity: A Case of Solid-Oncocytic Epithelial-Myoepithelial Carcinoma of the Parotid Gland Harboring a HRAS and Heterogeneous Terminating ARID1A Mutation.

Rupp NJ, Brada M, Skálová A, Bode B, Broglie MA, Morand GB, Rechsteiner M, Freiberger SN.

Head Neck Pathol. 2019 Jul 15. doi: 10.1007/s12105-019-01055-9. [Epub ahead of print]

PMID:
31309433
4.

Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma.

Bolck HA, Corrò C, Kahraman A, von Teichman A, Toussaint NC, Kuipers J, Chiovaro F, Koelzer VH, Pauli C, Moritz W, Bode PK, Rechsteiner M, Beerenwinkel N, Schraml P, Moch H.

Eur Urol Focus. 2019 Jun 29. pii: S2405-4569(19)30164-6. doi: 10.1016/j.euf.2019.06.009. [Epub ahead of print]

5.

Melanoma patients with additional primary cancers: a single-center retrospective analysis.

Dimitriou F, Mangana J, Curioni-Fontecedro A, Rechsteiner M, Turko P, Braun RP, Dummer R, Cheng PF.

Oncotarget. 2019 May 21;10(36):3373-3384. doi: 10.18632/oncotarget.26931. eCollection 2019 May 21.

6.

Microfluidic-Based Immunohistochemistry Combined With Next-Generation Sequencing on Diagnostic Tissue Sections for Detection of Tumoral BRAF V600E Mutation.

Leblond AL, Rechsteiner M, Jones A, Brajkovic S, Dupouy D, Soltermann A.

Am J Clin Pathol. 2019 Jun 5;152(1):59-73. doi: 10.1093/ajcp/aqz028.

PMID:
31065676
7.

Effects of exposure to ethanolic extract from Achyrocline satureioides (Lam.) D.C. flowers on reproductive and developmental parameters in Wistar rats.

Maciel MD, Inocêncio LCL, Rechsteiner MS, Jorge BC, Balin PDS, Kassuya RM, Heredia-Vieira SC, Cardoso CAL, Vieira MDC, Kassuya CAL, Arena AC.

J Toxicol Environ Health A. 2019;82(5):321-330. doi: 10.1080/15287394.2019.1593904. Epub 2019 Apr 2.

PMID:
30940006
8.

IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer.

Corrò C, Healy ME, Engler S, Bodenmiller B, Li Z, Schraml P, Weber A, Frew IJ, Rechsteiner M, Moch H.

J Pathol. 2019 Jul;248(3):377-389. doi: 10.1002/path.5267. Epub 2019 Apr 11.

9.
10.

Histological and molecular characterization of TFEB-rearranged renal cell carcinomas.

Wyvekens N, Rechsteiner M, Fritz C, Wagner U, Tchinda J, Wenzel C, Kuithan F, Horn LC, Moch H.

Virchows Arch. 2019 May;474(5):625-631. doi: 10.1007/s00428-019-02526-8. Epub 2019 Jan 31.

PMID:
30706129
11.

Energy and protein intake in 330 geriatric orthopaedic patients: Are the current nutrition guidelines applicable?

Rosenberger C, Rechsteiner M, Dietsche R, Breidert M.

Clin Nutr ESPEN. 2019 Feb;29:86-91. doi: 10.1016/j.clnesp.2018.11.016. Epub 2018 Dec 15.

PMID:
30661706
12.

Repeated Evolution Versus Common Ancestry: Sex Chromosome Evolution in the Haplochromine Cichlid Pseudocrenilabrus philander.

Böhne A, Weber AA, Rajkov J, Rechsteiner M, Riss A, Egger B, Salzburger W.

Genome Biol Evol. 2019 Feb 1;11(2):439-458. doi: 10.1093/gbe/evz003.

13.

Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing.

Zhong Q, Wagner U, Kurt H, Molinari F, Cathomas G, Komminoth P, Barman-Aksözen J, Schneider-Yin X, Rey JP, Vassella E, Rogel U, Diebold J, McKee T, Jochum W, Kashofer K, Hofman P, Zischka M, Moch H, Rechsteiner M, Wild PJ.

Pathol Res Pract. 2018 Jul;214(7):957-963. doi: 10.1016/j.prp.2018.05.020. Epub 2018 May 22.

PMID:
29807778
14.

New observations in tumor cell plasticity: mutational profiling in a case of metastatic melanoma with biphasic sarcomatoid transdifferentiation.

Rupp NJ, Rechsteiner M, Freiberger SN, Lenggenhager D, Urosevic M, Burger IA, Rushing EJ, Mihic-Probst D.

Virchows Arch. 2018 Oct;473(4):517-521. doi: 10.1007/s00428-018-2376-3. Epub 2018 May 21.

PMID:
29785541
15.

Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.

Velizheva NP, Rechsteiner MP, Valtcheva N, Freiberger SN, Wong CE, Vrugt B, Zhong Q, Wagner U, Moch H, Hillinger S, Schmitt-Opitz I, Soltermann A, Wild PJ, Tischler V.

Pathol Res Pract. 2018 Apr;214(4):572-578. doi: 10.1016/j.prp.2018.02.001. Epub 2018 Feb 16.

16.

Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features.

Rechsteiner M, Dedes K, Fink D, Pestalozzi B, Sobottka B, Moch H, Wild P, Varga Z.

J Cancer Res Clin Oncol. 2018 May;144(5):865-874. doi: 10.1007/s00432-018-2609-5. Epub 2018 Feb 17.

17.

The 11S Proteasomal Activator REGγ Impacts Polyglutamine-Expanded Androgen Receptor Aggregation and Motor Neuron Viability through Distinct Mechanisms.

Yersak JM, Montie HL, Chevalier-Larsen ES, Liu Y, Huang L, Rechsteiner M, Merry DE.

Front Mol Neurosci. 2017 May 24;10:159. doi: 10.3389/fnmol.2017.00159. eCollection 2017.

18.

Factor XIII Deficiency and Thrombocytopenia Are Frequent Modulators of Postoperative Clot Firmness in a Surgical Intensive Care Unit.

von Rappard S, Hinnen C, Lussmann R, Rechsteiner M, Korte W.

Transfus Med Hemother. 2017 Apr;44(2):85-92. doi: 10.1159/000468946. Epub 2017 Mar 22.

19.

A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients.

Zhong Q, Guo T, Rechsteiner M, Rüschoff JH, Rupp N, Fankhauser C, Saba K, Mortezavi A, Poyet C, Hermanns T, Zhu Y, Moch H, Aebersold R, Wild PJ.

Sci Data. 2017 Mar 14;4:170014. doi: 10.1038/sdata.2017.14.

20.

Detecting circulating tumor DNA in renal cancer: An open challenge.

Corrò C, Hejhal T, Poyet C, Sulser T, Hermanns T, Winder T, Prager G, Wild PJ, Frew I, Moch H, Rechsteiner M.

Exp Mol Pathol. 2017 Apr;102(2):255-261. doi: 10.1016/j.yexmp.2017.02.009. Epub 2017 Feb 23.

PMID:
28214514
21.

Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.

Valtcheva N, Lang FM, Noske A, Samartzis EP, Schmidt AM, Bellini E, Fink D, Moch H, Rechsteiner M, Dedes KJ, Wild PJ.

BMC Cancer. 2017 Jan 19;17(1):66. doi: 10.1186/s12885-017-3054-6.

22.

VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.

Razafinjatovo CF, Stiehl D, Deininger E, Rechsteiner M, Moch H, Schraml P.

Oncotarget. 2017 Feb 7;8(6):10199-10212. doi: 10.18632/oncotarget.14372.

23.

Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.

Velizheva NP, Rechsteiner MP, Wong CE, Zhong Q, Rössle M, Bode B, Moch H, Soltermann A, Wild PJ, Tischler V.

Cancer Cytopathol. 2017 Jan;125(1):30-40. doi: 10.1002/cncy.21771. Epub 2016 Sep 16.

24.

Liver cancer with concomitant TP53 and CTNNB1 mutations: a case report.

Friemel J, Rechsteiner M, Bawohl M, Frick L, Müllhaupt B, Lesurtel M, Weber A.

BMC Clin Pathol. 2016 Jun 1;16:7. doi: 10.1186/s12907-016-0029-5. eCollection 2016.

25.

Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.

Zhong Q, Rüschoff JH, Guo T, Gabrani M, Schüffler PJ, Rechsteiner M, Liu Y, Fuchs TJ, Rupp NJ, Fankhauser C, Buhmann JM, Perner S, Poyet C, Blattner M, Soldini D, Moch H, Rubin MA, Noske A, Rüschoff J, Haffner MC, Jochum W, Wild PJ.

Sci Rep. 2016 Apr 7;6:24146. doi: 10.1038/srep24146.

26.

Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer.

Rupp NJ, Schüffler PJ, Zhong Q, Falkner F, Rechsteiner M, Rüschoff JH, Fankhauser C, Drach M, Largo R, Tremp M, Poyet C, Sulser T, Kristiansen G, Moch H, Buhmann J, Müntener M, Wild PJ.

J Pathol Inform. 2016 Jan 29;7:3. doi: 10.4103/2153-3539.175376. eCollection 2016.

27.

Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status.

Frauchiger AL, Mangana J, Rechsteiner M, Moch H, Seifert B, Braun RP, Dummer R, Goldinger SM.

Br J Dermatol. 2016 Apr;174(4):823-30. doi: 10.1111/bjd.14347. Epub 2016 Mar 2.

PMID:
26659191
28.

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM.

PLoS One. 2015 Oct 1;10(10):e0139438. doi: 10.1371/journal.pone.0139438. eCollection 2015.

29.

A versatile modular vector system for rapid combinatorial mammalian genetics.

Albers J, Danzer C, Rechsteiner M, Lehmann H, Brandt LP, Hejhal T, Catalano A, Busenhart P, Gonçalves AF, Brandt S, Bode PK, Bode-Lesniewska B, Wild PJ, Frew IJ.

J Clin Invest. 2015 Apr;125(4):1603-19. doi: 10.1172/JCI79743. Epub 2015 Mar 9.

30.

A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib.

Rechsteiner M, Wild P, Kiessling MK, Bohnert A, Zhong Q, Stahel RA, Moch H, Curioni-Fontecedro A.

Ann Oncol. 2015 Jan;26(1):246-8. doi: 10.1093/annonc/mdu471. Epub 2014 Oct 20. No abstract available.

31.

Intratumor heterogeneity in hepatocellular carcinoma.

Friemel J, Rechsteiner M, Frick L, Böhm F, Struckmann K, Egger M, Moch H, Heikenwalder M, Weber A.

Clin Cancer Res. 2015 Apr 15;21(8):1951-61. doi: 10.1158/1078-0432.CCR-14-0122. Epub 2014 Sep 23.

32.

Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing.

Rechsteiner M, Müller R, Reineke T, Goede J, Bohnert A, Zhong Q, Manz MG, Moch H, Wild PJ, Zimmermann DR, Tinguely M.

Exp Hematol Oncol. 2014 Jul 11;3:18. doi: 10.1186/2162-3619-3-18. eCollection 2014.

33.

KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation.

Ikenberg K, Valtcheva N, Brandt S, Zhong Q, Wong CE, Noske A, Rechsteiner M, Rueschoff JH, Caduff R, Dellas A, Obermann E, Fink D, Fuchs T, Krek W, Moch H, Frew IJ, Wild PJ.

J Pathol. 2014 Oct;234(2):239-52. doi: 10.1002/path.4390. Epub 2014 Jul 30.

PMID:
24930886
34.

Automated assessment of β-cell area and density per islet and patient using TMEM27 and BACE2 immunofluorescence staining in human pancreatic β-cells.

Rechsteiner MP, Floros X, Boehm BO, Marselli L, Marchetti P, Stoffel M, Moch H, Spinas GA.

PLoS One. 2014 Jun 6;9(6):e98932. doi: 10.1371/journal.pone.0098932. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e109467.

35.

Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.

Rössle M, Sigg M, Rüschoff JH, Wild PJ, Moch H, Weber A, Rechsteiner MP.

Virchows Arch. 2013 Nov;463(5):623-31. doi: 10.1007/s00428-013-1492-3. Epub 2013 Oct 2.

PMID:
24085553
36.

Depletion of the 26S proteasome adaptor Ecm29 increases Toll-like receptor 3 signaling.

Gorbea C, Rechsteiner M, Vallejo JG, Bowles NE.

Sci Signal. 2013 Oct 1;6(295):ra86. doi: 10.1126/scisignal.2004301.

PMID:
24084648
37.

Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.

Zimmermann AK, Camenisch U, Rechsteiner MP, Bode-Lesniewska B, Rössle M.

Cancer Cytopathol. 2014 Jan;122(1):48-58. doi: 10.1002/cncy.21352. Epub 2013 Sep 4.

38.

TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.

Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A.

Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18.

PMID:
23965232
39.

KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics.

Rechsteiner M, von Teichman A, Rüschoff JH, Fankhauser N, Pestalozzi B, Schraml P, Weber A, Wild P, Zimmermann D, Moch H.

J Mol Diagn. 2013 May;15(3):299-311. doi: 10.1016/j.jmoldx.2013.02.001. Epub 2013 Mar 24.

40.

The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.

Casagrande S, Ruf M, Rechsteiner M, Morra L, Brun-Schmid S, von Teichman A, Krek W, Schraml P, Moch H.

J Pathol. 2013 Mar;229(4):525-34. doi: 10.1002/path.4107. Epub 2013 Jan 21.

41.

p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans.

Wild PJ, Ikenberg K, Fuchs TJ, Rechsteiner M, Georgiev S, Fankhauser N, Noske A, Roessle M, Caduff R, Dellas A, Fink D, Moch H, Krek W, Frew IJ.

EMBO Mol Med. 2012 Aug;4(8):808-24. doi: 10.1002/emmm.201101063. Epub 2012 Jun 8.

42.

Reliable detection of subclonal single-nucleotide variants in tumour cell populations.

Gerstung M, Beisel C, Rechsteiner M, Wild P, Schraml P, Moch H, Beerenwinkel N.

Nat Commun. 2012 May 1;3:811. doi: 10.1038/ncomms1814.

PMID:
22549840
43.

Characterization of periostin isoform pattern in non-small cell lung cancer.

Morra L, Rechsteiner M, Casagrande S, von Teichman A, Schraml P, Moch H, Soltermann A.

Lung Cancer. 2012 May;76(2):183-90. doi: 10.1016/j.lungcan.2011.10.013. Epub 2011 Nov 12.

PMID:
22079858
44.

Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass.

Esterházy D, Stützer I, Wang H, Rechsteiner MP, Beauchamp J, Döbeli H, Hilpert H, Matile H, Prummer M, Schmidt A, Lieske N, Boehm B, Marselli L, Bosco D, Kerr-Conte J, Aebersold R, Spinas GA, Moch H, Migliorini C, Stoffel M.

Cell Metab. 2011 Sep 7;14(3):365-77. doi: 10.1016/j.cmet.2011.06.018.

45.

Relevance of periostin splice variants in renal cell carcinoma.

Morra L, Rechsteiner M, Casagrande S, Duc Luu V, Santimaria R, Diener PA, Sulser T, Kristiansen G, Schraml P, Moch H, Soltermann A.

Am J Pathol. 2011 Sep;179(3):1513-21. doi: 10.1016/j.ajpath.2011.05.035. Epub 2011 Jul 18.

46.

VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations.

Rechsteiner MP, von Teichman A, Nowicka A, Sulser T, Schraml P, Moch H.

Cancer Res. 2011 Aug 15;71(16):5500-11. doi: 10.1158/0008-5472.CAN-11-0757. Epub 2011 Jun 29.

47.

Out with the old, in with the new? Comparing methods for measuring protein degradation.

Yewdell JW, Lacsina JR, Rechsteiner MC, Nicchitta CV.

Cell Biol Int. 2011 May;35(5):457-62. doi: 10.1042/CBI20110055. Review.

48.

Selective degradation of aggregate-prone CryAB mutants by HSPB1 is mediated by ubiquitin-proteasome pathways.

Zhang H, Rajasekaran NS, Orosz A, Xiao X, Rechsteiner M, Benjamin IJ.

J Mol Cell Cardiol. 2010 Dec;49(6):918-30. doi: 10.1016/j.yjmcc.2010.09.004. Epub 2010 Sep 21.

49.

A protein interaction network for Ecm29 links the 26 S proteasome to molecular motors and endosomal components.

Gorbea C, Pratt G, Ustrell V, Bell R, Sahasrabudhe S, Hughes RE, Rechsteiner M.

J Biol Chem. 2010 Oct 8;285(41):31616-33. doi: 10.1074/jbc.M110.154120. Epub 2010 Aug 3.

50.

TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification.

Zauner L, Melroe GT, Sigrist JA, Rechsteiner MP, Dorner M, Arnold M, Berger C, Bernasconi M, Schaefer BW, Speck RF, Nadal D.

Oncogene. 2010 Aug 12;29(32):4588-98. doi: 10.1038/onc.2010.203. Epub 2010 May 31.

PMID:
20514021

Supplemental Content

Loading ...
Support Center